Literature DB >> 16904975

CD40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells.

Hong Chai1, Shaoyu Yan, Hao Wang, Rongxin Zhang, Peter H Lin, Qizhi Yao, Changyi Chen.   

Abstract

BACKGROUND: Recently, CD40 ligand (CD40L) and its receptor CD40 have been implicated in atherosclerosis. Clinical data showed that elevated CD40L levels are associated with a high risk of cardiovascular events. The aim of this study was to investigate whether CD40L could affect the expression of its membrane receptor CD40 as a feedback mechanism by which CD40L could enhance its functions in human coronary artery endothelial cells (HCAECs).
METHODS: The HCAECs were treated with human soluble CD40L, and the messenger RNA (mRNA) and protein levels of CD40 were determined by real-time polymerase chain reaction and Western blot analysis, respectively. The specific effect of CD40L was confirmed by a blocking experiment with antibody against CD40L. Involvements of oxidative stress and mitogen-activated protein kinases (MAPKs) were also studied with antioxidant seleno-L-methionine (SeMet) and MAPK inhibitors such as extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor.
RESULTS: When HCAECs were cultured with CD40L (5 microg/mL) for 24 hours, CD40 mRNA levels were increased by 79% compared with controls (P < .05). Similarly, Western blot analysis showed an 80% increase in CD40 protein levels (P < .05). The CD40L-induced increase in CD40 mRNA levels were blocked specifically by anti-CD40L antibody. Antioxidant SeMet and specific ERK1/2 inhibitor (PD98059) also effectively blocked CD40L-induced CD40 mRNA increase.
CONCLUSIONS: These data demonstrate that clinically relevant concentration of CD40L increased the expression of its receptor CD40 in HCAECs. The CD40L-induced upregulation of CD40 may be mediated by oxidative stress and ERK1/2 activation. This study suggests a new mechanism by which CD40L could enhance its biologic functions in the vascular system and contribute to endothelial dysfunction and vascular disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904975     DOI: 10.1016/j.surg.2006.03.016

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

Review 1.  CD40/CD40L system and vascular disease.

Authors:  F Santilli; S Basili; P Ferroni; G Davì
Journal:  Intern Emerg Med       Date:  2007-11-28       Impact factor: 3.397

2.  Dyad of CD40/CD40 ligand fosters neuroinflammation at the blood-brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis.

Authors:  Servio H Ramirez; Shongshan Fan; Holly Dykstra; Nancy Reichenbach; Luis Del Valle; Raghava Potula; Richard P Phipps; Sanjay B Maggirwar; Yuri Persidsky
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

3.  Increased serum concentrations of Soluble CD40 Ligand as a prognostic marker in patients with Acute Coronary Syndrome.

Authors:  Priya Gururajan; Prema Gurumurthy; Pradeep Nayar; Sai Babu; A Sarasabharati; Dolice Victor; K M Cherian
Journal:  Indian J Clin Biochem       Date:  2009-09-16

4.  Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells.

Authors:  Changyi Chen; Hong Chai; Xinwen Wang; Jun Jiang; Md Saha Jamaluddin; Dan Liao; Yuqing Zhang; Hao Wang; Uddalak Bharadwaj; Sheng Zhang; Min Li; Peter Lin; Qizhi Yao
Journal:  Blood       Date:  2008-07-24       Impact factor: 22.113

5.  Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD).

Authors:  Jon Salemi; Demian F Obregon; Anthony Cobb; Spenser Reed; Edin Sadic; Jingji Jin; Francisco Fernandez; Jun Tan; Brian Giunta
Journal:  Mol Neurodegener       Date:  2011-01-11       Impact factor: 14.195

6.  The human blood DNA methylome identifies crucial role of β-catenin in the pathogenesis of Kawasaki disease.

Authors:  Kuang-Den Chen; Ying-Hsien Huang; Mindy Ming-Huey Guo; Tzu-Yang Lin; Wei-Teng Weng; Hsiang-Jen Yang; Kuender D Yang; Ho-Chang Kuo
Journal:  Oncotarget       Date:  2018-06-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.